LVTX (LAVA Therapeutics NV) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. LAVA Therapeutics NV's Free Cash Flow for the three months ended in Sep. 2024 was $-8.63 Mil. LAVA Therapeutics NV's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, LAVA Therapeutics NV's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, LAVA Therapeutics NV's current FCF Yield % is -90.65%.

The historical rank and industry rank for LAVA Therapeutics NV's FCF Margin % or its related term are showing as below:

LVTX' s FCF Margin % Range Over the Past 10 Years
Min: -586.53 Med: -405.76 Max: 17.82
Current: -389.43

During the past 5 years, the highest FCF Margin % of LAVA Therapeutics NV was 17.82%. The lowest was -586.53%. And the median was -405.76%.

LVTX's FCF Margin % is ranked worse than
63.35% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs LVTX: -389.43

LAVA Therapeutics NV FCF Margin % Historical Data

The historical data trend for LAVA Therapeutics NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV FCF Margin % Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-261.78

-549.74

17.82

-586.53

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-13,420.75	-2,964.59	-16.09	-	-

Competitive Comparison of LAVA Therapeutics NV's FCF Margin %

For the Biotechnology subindustry, LAVA Therapeutics NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's FCF Margin % falls into.

LAVA Therapeutics NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

LAVA Therapeutics NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-39.702	/	6.769
	=	-586.53 %

LAVA Therapeutics NV's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-8.63	/	0
	=	%

LAVA Therapeutics NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.